104,000+ cardiology appointments screened; 13.4% of patients identified for lipid-lowering treatment intensification, improving adherence to guidelines nationwide.

AI-driven screening for early signs of ALS, when therapy to retain functions and slow disease progress is most efficient.

80× increase in naloxone prescriptions in 6 months by empowering patients and pharmacists through digital technologies.

A secure digital PHIPA-compliant platform for SDM workflow that pairs patient and clinician questionnaires to surface priorities, compare perspectives, and support guideline-aligned treatment decisions—while generating real-world evidence and Patient Reported Outcomes. In a rare-disease quality-improvement rollout (as of Oct 6, 2025), 17 specialists enrolled 45 patients, and 24/27 completed patient–physician pairs led to a treatment modification or discontinuation.